AXSM earnings — 2026-08-10

COVERAGE GAP — print not explicitly confirmed in tonight's pulls. The same-day analyst tape is consistent with a report having landed: TD Cowen raised its target to $300 from $275 (Buy), RBC nudged to $304 from $302, Mizuho trimmed to $306 from $310, and BMO initiated at Outperform — plus Axsome initiated the FOCUS-2 Phase 3 pediatric trial of solriamfetol (ADHD). No EPS/revenue actuals were stated in any pulled item, so this stays scheduled pending tomorrow's fill. Analyst direction reads constructive on balance.

Sources: TheFly/stockanalysis analyst items (Aug 10) in data/stocks/AXSM/news/latest.json (fetched 2026-08-11 UTC).